<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948023</url>
  </required_header>
  <id_info>
    <org_study_id>LVPEI-2014-1 Version 1 15Jan14</org_study_id>
    <nct_id>NCT02948023</nct_id>
  </id_info>
  <brief_title>Stem Cells Therapy for Corneal Blindness</brief_title>
  <acronym>ExCell</acronym>
  <official_title>Ex-vivo Cultivated Limbal Stem Cell Transplantation for Treatment of Superficial Corneal Pathologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.V. Prasad Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>L.V. Prasad Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a investigative initiated, comparative pilot clinical trial to ascertain the safety
      of application of ex-vivo cultivated limbal stem cells in human eyes for treating different
      superficial corneal pathologies. Pre-clinical work in murine models have already demonstrated
      efficacy of this technique in curing murine corneal pathologies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective interventional study patients with superficial corneal pathologies like
      scars, ulcers and burns will undergo a surgical procedure. Limbal ring from a cadaveric donor
      tissue, which is therapeutically accepted and serologically tested, is collected. This tissue
      will then be cultivated in the stem cell biology laboratory using standardized culture
      technique. Briefly the limbal tissue will be cut up into small pieces and digested overnight
      using an enzyme (Collagenase L). The cells obtained from the digest will be cultured on a
      petri-dish using 2% serum and growth factors. The cultured cells will be passaged three times
      to remove all epithelial cells from the culture. In the second procedure, the central corneal
      epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration
      of 5x10^3 cells/uL diluted in the thrombin component of fibrin glue (TISEEL, Baxter) will be
      applied to the debrided corneal stroma. A soft bandage contact lens will be placed over the
      cornea at the end of the procedure. The patient will receive topical antibiotic and steroid
      eye drops in the post-operative period. Periodic comprehensive ophthalmic evaluation along
      with anterior segment optical coherence tomography (ASOCT) scanning and slit-lamp photography
      will be done at day 1, day 7, day 45 and day 90.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular or systemic adverse effects</measure>
    <time_frame>until 3months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual improvement after treatment.</measure>
    <time_frame>until 3months after surgery</time_frame>
    <description>Checking for the improvement in visual acuity that will be calculated using LogMAR chart (where 20/20 vision is normal).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Corneal Injuries</condition>
  <condition>Corneal Burns</condition>
  <condition>Corneal Scars and Opacities</condition>
  <arm_group>
    <arm_group_label>Standard Surgical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Includes the control group that fulfills the inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex-vivo cultivated limbal stem cell pool</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ex-vivo cultivated limbal stem cell pool</intervention_name>
    <description>0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.</description>
    <arm_group_label>Ex-vivo cultivated limbal stem cell pool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female participants who are aged between 18-60 years.

          2. Patients who are having with unilateral blindness due to superficial (defined as
             involving the anterior 200 microns of the corneal stroma on ASOCT imaging) corneal
             wounds, ulcers, burns and scars.

          3. Eyes with otherwise normal.

        Exclusion Criteria:

          1. Active infection, proven by microbiology.

          2. Unknown etiology, post-herpetic eye disease or eyes with active intra-ocular
             inflammation.

          3. Children (&lt;18 years of age).

          4. Inability/refusal to give written informed consent or to undergo any of the anterior
             segment imaging tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sayan Basu, MBBS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>LV Prasad Eye Institiute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivek Singh, MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LV Prasad Eye Institiute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sayan Basu, MBBS, MS</last_name>
    <phone>9140-30612625</phone>
    <phone_ext>2625</phone_ext>
    <email>sayanbasu@lvpei.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivek Singh, MSc PhD</last_name>
    <phone>9140-30612286</phone>
    <phone_ext>2286</phone_ext>
    <email>viveksingh@lvpei.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LV Prasad Eye Institute</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayan Basu, MBBS, MS</last_name>
      <phone>+9140 3061 2625</phone>
      <phone_ext>2625</phone_ext>
      <email>sayanbasu@lvpei.org</email>
    </contact>
    <contact_backup>
      <last_name>Vivek Singh Singh, MSc PhD</last_name>
      <phone>+9140 3061 2286</phone>
      <phone_ext>2286</phone_ext>
      <email>viveksingh@lvpei.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Basu S, Hertsenberg AJ, Funderburgh ML, Burrow MK, Mann MM, Du Y, Lathrop KL, Syed-Picard FN, Adams SM, Birk DE, Funderburgh JL. Human limbal biopsy-derived stromal stem cells prevent corneal scarring. Sci Transl Med. 2014 Dec 10;6(266):266ra172. doi: 10.1126/scitranslmed.3009644.</citation>
    <PMID>25504883</PMID>
  </results_reference>
  <results_reference>
    <citation>Basu S, Damala M, Singh V. Limbal Stromal Stem Cell Therapy for Acute and Chronic Superficial Corneal Pathologies: Early Clinical Outcomes of The Funderburgh Technique. Investigative Ophthalmology &amp; Visual Science. 2017 Jun 23;58(8):3371-337</citation>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>March 3, 2018</last_update_submitted>
  <last_update_submitted_qc>March 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>L.V. Prasad Eye Institute</investigator_affiliation>
    <investigator_full_name>Vivek Singh</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Injuries</mesh_term>
    <mesh_term>Corneal Opacity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

